McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
NOVATO, Calif., Jan. 04, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 7:30 am PT in San Francisco.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Danielle Keatley 844-758-7273
